furosemide infusion

DRUG2 trials

Sponsors

University of Siena, Reprieve Cardiovascular, Inc

Conditions

Acute Decompensated Heart FailureAcute Heart Failure

Phase 3

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

RecruitingNCT06898515

Reprieve Cardiovascular, IncAcute Decompensated Heart Failure

Start: 2025-07-14End: 2027-12-31Target: 400Updated: 2025-11-26

Phase 4

Loop Diuretics Administration and Acute Heart Failure

CompletedNCT01441245

University of SienaAcute Heart Failure

Start: 2010-04-30End: 2017-12-28Updated: 2018-01-23

Related Papers

Loop Diuretic Administration in Patients with Acute Heart Failure and Reduced Systolic Function: Effects of Different Intravenous Diuretic Doses and Diuretic Response Measurements

Journal of Clinical Medicine2019-11-026 citations

Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome

Journal of Cardiovascular Medicine2018-12-1112 citations

The prognostic role of different renal function phenotypes in patients with acute heart failure.

2018-11-2310 citations

The paradox of transient worsening renal function in patients with acute heart failure: the role of B-type natriuretic peptide and diuretic response.

2017-11-0111 citations

Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction.

2017-07-1743 citations

Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial.

2014-06-2846 citations